| |
| |
|
 |
 | | 08/09/2010 | | TIME: 15:22:31 | | LAST | 17.60 € | | OPEN | 17.07 € | | CHANGE | 3.53 % |
|
|
 |
|
|
|
| |
|
| |
Patrik De Haes, MD I Chief Executive Officer
| Patrik De Haes has over 20 years of experience in the global health
care industry, covering product development, marketing and general management. He joined
from Roche in Switzerland, where he was Head of the Global Insulin Infusion business. Before that,
Dr. De Haes was President and
CEO of Disetronic Medical Systems
Inc, a leading company in insulin
infusion therapy, in Minneapolis, USA. At Sandoz Pharma (now
Novartis) in Switzerland, he led
the global development and
commercialization of the first biotech product for that company. Dr. De Haes holds a degree in Medicine from the University of
Leuven. I top |
 |
|
 |
Chris
Buyse I Chief Financial Officer
 |
Chris Buyse brings to ThromboGenics 20 years experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign, where he coordinated its acquisition by BASF in early 2007. Before this, Mr. Buyse was Finance Director of WorldCom/MCI Belux, a European subsidiary of one of the world’s largest telecom companies, and was CFO and interim CEO of Keyware Technologies, reporting to the President of the Board. In addition, he held several financial positions as financial controller and internal auditor at Spector Photo Group, Suez Lyonnaise des Eaux and Unilever. I top |
|
|
Stuart Laermer, MSc, MBA I Chief
Business Officer
| Stuart Laermer is Chief Business Officer of ThromboGenics, responsible for the Company’s commercial activities, including partnering, licensing and business development. Mr. Laermer has more than 20 years of global experience in the commercialization of novel technologies. He was formerly Vice President, Business Development at Synthon Chiragenics and Physiome Sciences, where he was a member of the founding management team. He has also been Director, Business Development at Hoffmann-La Roche and Director, Biotechnology & Specialty Products at Fisher Scientific. Mr. Laermer received his MSc in Chemical Engineering from Columbia University, and MBA from New York University. I top |
 |
|
|
Steve
Pakola, MD I Chief
Medical Officer
 |
Steve Pakola, who joined the Company in May 2000, is the Chief Medical Officer of ThromboGenics. Dr. Pakola is a licensed physician with extensive clinical trial experience, including over 11 years in pharma/biotech clinical development. Prior to joining the Company, Dr. Pakola was Associate Director, Cardiovascular Clinical Research, at Boehringer-Ingelheim Pharmaceuticals, where he served as global medical lead on the lipid-lowering development program, as well as U.S. medical lead for the direct thrombin inhibitor development program. Prior to Boehringer-Ingelheim, Dr. Pakola also served in senior-level clinical development positions at Quintiles Cardiovascular Therapeutics and Organon, Inc. Dr Pakola received his MD degree from the University of Pennsylvania. I top |
|
|
Jean
Marie Stassen, PhD I Head of Pre-Clinical Development
| Jean Marie Stassen is responsible for ThromboGenics' preclinical program capability. Jean Marie joined ThromboGenics in 2001 and is co-founder and member of the
board of FlandersBio. He holds a degree in medical sciences and has over 15 years of pharma/biotech drug development experience. Dr. Stassen was previously at Boehringer Ingelheim Pharma, Germany, where he served as a research
project leader for the cardiovascular therapeutic area. Together with Prof. Collen, Dr. Stassen worked on the characterization of tPA and
staphylokinase. He is author and co-author of more than 100 papers in peer-reviewed journals, and more than 250 patents and patent applications. I top |
 |
|
|
Andy De Deene I Head of Program Management
 |
Andy De Deene previously worked as both Manager and Director for both the Janssen Research Foundation and XCellentis in Belgium and has considerable experience in different areas of drug development such as clinical development, pharmacovigilance and Medical Affairs. Andy holds a MD from the University of Ghent, was trained as a dermatologist at the University of Cologne, and obtained an executive MBA at the Vlerick Management School. I top |
|
|
Phil Challis I Head CMC
| Phil Challis is head of chemistry, manufacturing and controls (CMC ). Phil brings over 20 years of experience in product development of biological entities. Phil has previously worked for UCB Pharma in a management role, and brings ThromboGenics experience in defining manufacturing strategy and planning late phase regulatory submissions. Phil has managed manufacturing programmes during early and late phase clinical trials and post commercialization. Phil has previously held key positions in product development functions at Lonza Biologics and Celltech, and brings valuable experience to ThromboGenics' strategic manufacturing policy. I top |
 |
|
Laurence Raemdonck I HR Manager
 |
Laurence Raemdonck joined ThromboGenics as HR Manager in 2007. She is licensed in Germanic Philology and possesses a degree in Human Resources. She was previously employed in the telecom sector at Verizon Business. She has the responsibility for all areas related to human resources such as compensation, hiring, performance management, benefits, organization development, administration and training. As HR Manager, she is advocate for both the Company and its people, and therefore performs a constant balancing act in order to meet both needs successfully. I top |
|
| |
|
|
| |
 All rights reserved © Thrombogenic 2006 Last update:
August 11, 2009
Inspired by Echo |
|
|
